Author Archive

RIGL license agreement. NLNK interim Phase 3 data due early 2013. FURX initiates Phase 3 IBS trial. APPY CVM offerings + PTN

Jun 20, 2012 No Comments

AstraZeneca and Rigel Pharmaceuticals, Inc., (Nasdaq: RIGL) announced a worldwide license agreement for the global development and commercialization of R256, which is being investigated as a treatment for moderate to severe chronic asthma. AstraZeneca will have exclusive rights to commercialize R256 around the world. Rigel will receive an upfront payment of $1 million with an additional $8.25 million in early milestone payments […]

Read more

INFI stops Phase 2 trials. RPTP Phase 2/3 Cysteamine data due 1H 2014 + CTIC news

Jun 19, 2012 No Comments

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced that following disappointing initial data it will be stopping its Phase 2 trials of saridegib (IPI-926) in patients with metastatic or locally advanced, inoperable chondrosarcoma and in patients with myelofibrosis. Cell Therapeutics, Inc. (NASDAQ and MTA: CTIC) announced that the University of Washington has begun enrolment in a Phase 2 trial of […]

Read more

SNSS interim Phase 3 VALOR analysis due September. DYAX discontinues Phase 2 ecallantide. AEGR prices offering.

Jun 15, 2012 No Comments

Dyax Corp. (NASDAQ: DYAX) announced that it will discontinue its Phase 2 trial of ecallantide in the acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema following an interim analysis showing it not to be statistically effective. Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) said that it expects interim analysis of its Phase 3 VALOR trial of vosaroxin, in patients with […]

Read more

RPTP late January 2013 likely PDUFA date. AEGR proposed offering

Jun 14, 2012 No Comments

Raptor Pharmaceutical Corp.  (Nasdaq:RPTP) today that the FDA accepted its New Drug Application (“NDA”) for Cysteamine Bitartrate Delayed-release Capsules (RP103), for the potential treatment of nephropathic cystinosis. A standard 10-month review was issued. A PDUFA date was not issued but the company released a press release on March 30, 2012 that it had filed its […]

Read more

ALXA reverse split. ALKS JNJ initiate Phase 3 schizophrenia. NYMX commences Phase 2 prostate cancer enrolment

Jun 13, 2012 No Comments

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced a 1-for-10 reverse split of its common stock effective immediately. The number of common stock outstanding will correspondingly be reduced from approximately 119.6 million to approximately 12.0 million. Alkermes plc (NASDAQ: ALKS) announced that Janssen Research & Development, LLC has initiated a Phase 3 trial for a three-month formulation of INVEGA SUSTENNA(paliperidone palmitate), an injectable medicine […]

Read more

Chatroom has been disabled

Jun 12, 2012 No Comments

I’ve decided to remove the chatroom from BioPharmCatalyst due to the high cost involved in maintaining the chatroom and a feeling that it doesn’t fit in with the philosophy of the website of giving unbiased tools for readers to use in their investing and trading decisions. I will continue to explore avenues to improve the website […]

Read more

BIOD reverse split. ZIOP initiates Phase 3 SCLC trial. BPAX plans further LibiGel trials + AVNR PLX news

Jun 12, 2012 No Comments

Biodel Inc. (Nasdaq:BIOD) announced that it will effect a one-for-four reverse split prior to the start of trading on June 12, 2012. The number of authorized shares of common stock will be adjusted to 25m. ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced that has initiated its Phase 3 MATISSE study (Multicenter Adaptive Trial Investigating Small cell lung cancer Survival Endpoints), of palifosfamide for the […]

Read more

EXEL files shelf. CHTP cost-saving measures. ALNY initiates Phase 2 trial for ATTR.

Jun 08, 2012 No Comments

EXELIXIS INC (NASDAQ: EXEL) filed a mixed shelf today on a Form S‑3ASR to register an unspecified amount of equity or debt securities. The shelf becomes effective automatically without the requirement of review by the SEC. Companies classed as “well known seasoned issuers” (“WKSI”) may file an automatic shelf registration (ASR), which allows it to not specify the dollar […]

Read more

FDA approves XNPT Horizant. OREX initiates cardio outcomes trial. AIS to transfer to NASDAQ. ACHN CMO resigns + NBY news

Jun 07, 2012 No Comments

GlaxoSmithKline plc (GSK) and XenoPort, Inc. (Nasdaq:XNPT) announced the FDA approved their supplemental new drug application of Horizant for the management of postherpetic neuralgia (PHN) in adults. Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced that it has initiated its cardiovascular outcomes trial, called the Light-Study,  evaluating the occurrence of major adverse cardiovascular events (MACE) in patients taking Contrave, for the treatment of obesity. […]

Read more

ARIA MRK receive CRL. VVUS Qnexa MAA decision delayed. ABT NBIX initiate Phase 3 endometriosis. DYAX analysis of ecallantide due within 3 months + SGYP

Jun 06, 2012 No Comments

Merck (NYSE: MRK) announced that the FDA issued a complete response letter (CRL) regarding the New Drug Application (NDA) for ridaforolimus for patients with metastatic soft tissue or bone sarcoma. The letter stated that additional clinical trial would need to be conducted to further assess safety and efficacy. ARIAD Pharmaceuticals, Inc (Nasdaq: ARIA) has a license […]

Read more

BPAX reverse split. AVII proposes name change. MRNA winding down operations + ONTY news

Jun 01, 2012 No Comments

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced it will effect a 1-for-6 reverse split of its common stock on Monday, June 4, 2012. The reverse stock split will reduce the number of shares outstanding from approximately 120.8m to approximately 20.1m shares. The number of authorized shares will remain unchanged. The company had until July 30, 2012 to push […]

Read more